Chester County News and Community Website
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced encouraging updates from the ongoing Phase 1/2 upliFT-D clinical trial for PBFT02, a one-time gene therapy for frontotemporal dementia (FTD) …
Passage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has shared encouraging interim results from its Phase 1b FURTHER trial, which investigates firmonertinib as a first-line monotherapy for non-small cell …
ArriVent BioPharma Reports Promising Results from Phase 1b Trial for Firmonertinib in NSCLC Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and efficacy of ATI-052, an investigational bispecific anti-TSLP/IL-4R antibody that could …
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has initiated an immediate review of clinical trials involving the international transfer of Americans’ living cells for genetic engineering and subsequent …
FDA Investigates Clinical Trials Sending U.S. DNA Overseas Read More
PHOENIXVILLE, PA — PleoPharma, Inc. shared encouraging findings from its Phase 2b clinical trial of PP-01, a novel treatment for Cannabis Withdrawal Syndrome (CWS), during the 2025 annual meeting of …
PleoPharma Presents Promising Phase 2b Data on PP-01 for Cannabis Withdrawal Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced promising topline results from its Phase 2 Explore-CKD trial, evaluating lorundrostat as a treatment for hypertension in patients with chronic kidney …
Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the publication of findings from its Phase 2 SEISMiC B study on istaroxime in the Journal of Heart and Lung …
Windtree Therapeutics Announces Promising Phase 2 Study Results for Istaroxime Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2/3 pivotal confirmatory trial of OCU410ST, an innovative …
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease Read More
WILMINGTON, DE — First clinical data for INCA033989, a novel monoclonal antibody from Incyte (Nasdaq: INCY) targeting CALR-mutant myeloproliferative neoplasms (MPNs), were presented at the European Hematology Association (EHA) Congress …
Promising Results for Novel Therapy in CALR-Mutant Myeloproliferative Neoplasms Read More WILMINGTON, DE — Groundbreaking results from the Phase 3 POD1UM-303/InterAACT 2 trial have been published in The Lancet, showcasing the efficacy of retifanlimab (Zynyz®) in combination with carboplatin and paclitaxel …
New Phase 3 Trial Data Positions Retifanlimab as Breakthrough in Advanced SCAC Treatment Read More